Lirafugratinib (Lyrfigtu ® ): a first-in-class, highly selective FGFR2 inhibitor approved for advanced cholangiocarcinoma

Neuroretina · Springer Nature · 2026-11-14 · DOI: 10.1007/s00044-026-03641-3

Аннотация

Fibroblast growth factor receptor 2 (FGFR2) fusions or rearrangements are validated oncogenic drivers in intrahepatic cholangiocarcinoma. The US FDA recently approved the highly selective inhibitor lirafugratinib (Lyrfigtu ® ) for adult patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma harboring an FGFR2 fusion or other rearrangement. First-generation pan-FGFR inhibitors are limited by FGFR1-mediated hyperphosphatemia and rapid acquired resistance, highlighting the need for FGFR2-selective inhibitors. Guided by long-timescale molecular dynamics simulations, researchers identified differential dynamics in the kinase P-loop between FGFR1 and FGFR2. Lirafugratinib was rationally engineered to covalently engage Cys491 in FGFR2, while stabilizing the FGFR1 P-loop in a conformation that locks its corresponding cysteine out of reactive reach. This structural ingenuity confers > 250-fold selectivity over FGFR1, thus mitigating phosphate toxicity and effectively bypassing steric clashes caused by clinical gatekeeper mutations (e.g., V564F). In the pivotal ReFocus trial, lirafugratinib demonstrated robust, durable clinical efficacy alongside a highly manageable safety profile, and was thus approved without undergoing phase 3 clinical trials.

Читать у издателя →

Похожие статьи